Baldwidx Off the top of my head I've come up with 10...

Baldwidx

Off the top of my head I've come up with 10 possibilities, but there's possibly more. Here's my list and a link to an earlier post which is relevant to the subject.

1. Outright upfront acquisition of NEU
2. Structured acquisition of NEU (M & A with earn-outs) - substantial upfront is paid with further payments contingent on success in milestones such as Phase 3 success and/or FDA approval. Such a deal may also make provision for any Priority Review Voucher received. Over 80% of pharma acquisitions contain some type of earn-out. About 80% of earn-out payments are made within 1 to 3 years of closing of acquisition.
3. Substantial placement in NEU, funding provided for Phase 3 and option to buy out company or asset at later date.
4. Outright acquisition of trofinetide
5. Outright acquisition of trofinetide + R & D partnership and option on NNZ-2591
6. Global licensing of trofinetide in all indications – upfront +milestones + licence fees on sales
7. Global licensing of trofinetide in all indications + R & D partnership and option on NNZ-2591.
8. Global licensing of trofinetide in Rett Syndrome only, possibly with an option for other indications.
9. Territorial-based licensing of trofinetide in Rett syndrome and potentially other indications. For example, ex-US licensing of trofinetide while NEU keeps or licenses separately in US.
10. NEU sources funds and goes it alone….

https://hotcopper.com.au/threads/license-or-buyout.2702167/?post_id=17033550#.WsXPPYhuaUk